- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00802724
Classification-Directed Treatment of Low Back Pain
October 18, 2012 updated by: Linda Van Dillen, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
The primary purpose of this proposal is to conduct a prospective, randomized, controlled clinical trial to examine whether or not treatment based on a person's direction-specific, impairment-based LBP classification is more effective than Non-specific treatment in improving short- (6 weeks) and long-term (6 and 12 months) outcomes in people with chronic LBP.
We hypothesize that treatment based on a person's direction-specific, impairment-based LBP classification (Classification-specific) will result in better outcomes than Non-specific treatment.
Our approach to classification-directed treatment is based on the proposal that a person's LBP is the result of adopting direction-specific strategies of movement and alignment of the spine which then are used repeatedly during the person's everyday activities.
The exposure of spine tissue to repeated loading in the same direction across a day is proposed to accelerate the accumulation of stress, microtrauma, and eventually LBP.
We also hypothesize that until the factors contributing to the use of the direction-specific strategies of the spine are modified, the LBP problem will persist or recur.
Identification of homogeneous subgroups of people with LBP will enhance 1) the power of clinical trials, 2) prognosis, and 3) the ability to identify mechanisms contributing to different LBP problems.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
101
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63108
- Washington University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- People who report a history of chronic LBP for a minimum of 12 months,currently are experiencing LBP symptoms but not in an acute recurrence,
- Between 18 and 60 years of age,
- Able to stand and walk without assistance,
- Able to understand and read English,
- Able to understand and sign a consent form
Exclusion Criteria:
- Any structural spinal deformity including scoliosis, kyphosis, or stenosis,
- A spinal fracture or dislocation,
- Osteoporosis,
- Ankylosing spondylitis,
- Rheumatoid arthritis,
- Disc herniation,
- Serious spinal complications such as tumor or infection,
- Previous spinal surgery,
- Frank neurological loss, i.e., weakness and sensory loss,
- Pain or paresthesia below the knee,
- Etiology of LBP other than the lumbar spine, e.g., hip joint,
- History of neurologic disease which required hospitalization,
- Active treatment for cancer,
- History of unresolved cancer,
- Pregnancy,
- Magnified symptom behavior,
- Worker's compensation or disability case,
- In litigation for the LBP problem,
- Referral from a specialized pain clinic source,
- Spondylolisthesis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1 Classification-directed treatment
People in the Classification-directed treatment will be treated based on their direction-specific LBP classification.
Treatment will consist of 3 primary components.
The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities.
The second component is education about the principles of tissue injury and healing and the need to keep active.
The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
|
People in the Classification-directed treatment will be treated based on their direction-specific LBP classification.
Treatment will consist of 3 primary components.
The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities.
The second component is education about the principles of tissue injury and healing and the need to keep active.
The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
|
|
Active Comparator: 2 Non-specific treatment
People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP.
The first component of treatment will consist of training in functional activities based on biomechanical principles.
The second component will include general education about low back pain.
The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
|
People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP.
The first component of treatment will consist of training in functional activities based on biomechanical principles.
The second component will include general education about low back pain.
The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modified Oswestry Disability Index for Low Back Pain (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
Functional limitation measure
|
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Kinematic measures of select movements and postures
Time Frame: Baseline, completion of treatment phase
|
Impairment level measure
|
Baseline, completion of treatment phase
|
|
Numeric pain rating scale (0-10 points)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
Impairment level measure
|
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
|
Medication use (yes, no)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
Impairment level measure
|
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
|
Days of low back pain-related time off (number)
Time Frame: Baseline, 6 months after treatment phase, 12 months after treatment phase
|
Impairment level measure; Question #5 from the Graded Chronic Pain Scale (Von Korff et al., Pain, 1990)
|
Baseline, 6 months after treatment phase, 12 months after treatment phase
|
|
Baecke Habitual Activity Measure (3-15 points)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
Impairment level measure
|
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
|
Fear Avoidance Beliefs Questionnaire Work subscale (0-42 points)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
Impairment level measure
|
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
|
SF-36 Physical Functioning subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
Disability level measure
|
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
|
SF-36 Role Functioning-Physical subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
Disability level measure
|
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
|
SF-36 Bodily Pain subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
Disability level measure
|
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
|
SF-36 General Health subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
Disability level measure
|
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
|
SF-36 Vitality subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
Disability level measure
|
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
|
SF-36 Social Functioning Subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
Disability level measure
|
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
|
SF-36 Role Functioning subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
Disability level measure
|
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
|
Fear Avoidance Beliefs Activity subscale (0-24 points)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
Impairment level measure
|
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
|
SF-36 Role Functioning-Emotional subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months, 12 months
|
Disability level measure
|
Baseline, completion of treatment phase, 6 months, 12 months
|
|
SF-36 Mental Health subscale (0-100%)
Time Frame: Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
Disability level measure
|
Baseline, completion of treatment phase, 6 months after treatment phase,12 months after treatment phase
|
|
Adherence to exercise (0-100%)
Time Frame: Second treatment visit, completion of treatment phase, 6 months after treatment phase, 12 months after treatment phase
|
Measure of the percentage of times the person reports adhering to performing the exercise as prescribed
|
Second treatment visit, completion of treatment phase, 6 months after treatment phase, 12 months after treatment phase
|
|
Adherence to training in performance of functional activities (0-100%)
Time Frame: Second treatment visit, completion of treatment phase, 6 months post-treatment phase, 12 months post-treatment phase
|
Measure of the percentage of times the person adhered to performing his/her functional activities as prescribed
|
Second treatment visit, completion of treatment phase, 6 months post-treatment phase, 12 months post-treatment phase
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Satisfaction with care (15-75 points)
Time Frame: Completion of treatment phase
|
Satisfaction with treatment
|
Completion of treatment phase
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Linda R Van Dillen, P.T., Ph.D., Washington University School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Henry SM, Van Dillen LR, Trombley AR, Dee JM, Bunn JY. Reliability of novice raters in using the movement system impairment approach to classify people with low back pain. Man Ther. 2013 Feb;18(1):35-40. doi: 10.1016/j.math.2012.06.008. Epub 2012 Jul 15.
- Harris-Hayes M, Holtzman GW, Earley JA, Van Dillen LR. Development and preliminary reliability testing of an assessment of patient independence in performing a treatment program: standardized scenarios. J Rehabil Med. 2010 Mar;42(3):221-7. doi: 10.2340/16501977-0505.
- Hoffman SL, Johnson MB, Zou D, Harris-Hayes M, Van Dillen LR. Effect of classification-specific treatment on lumbopelvic motion during hip rotation in people with low back pain. Man Ther. 2011 Aug;16(4):344-50. doi: 10.1016/j.math.2010.12.007. Epub 2011 Jan 20.
- Holtzman G, Harris-Hayes M, Hoffman SL, Zou D, Edgeworth RA, Van Dillen LR. Clinical examination procedures to determine the effect of axial decompression on low back pain symptoms in people with chronic low back pain. J Orthop Sports Phys Ther. 2012 Feb;42(2):105-13. doi: 10.2519/jospt.2012.3724. Epub 2011 Oct 25.
- Hoffman SL, Harris-Hayes M, Van Dillen LR. Differences in activity limitation between 2 low back pain subgroups based on the movement system impairment model. PM R. 2010 Dec;2(12):1113-8. doi: 10.1016/j.pmrj.2010.09.003.
- Hoffman SL, Johnson MB, Zou D, Van Dillen LR. Differences in end-range lumbar flexion during slumped sitting and forward bending between low back pain subgroups and genders. Man Ther. 2012 Apr;17(2):157-63. doi: 10.1016/j.math.2011.12.007. Epub 2012 Jan 17.
- Ravenna MM, Hoffman SL, Van Dillen LR. Low interrater reliability of examiners performing the prone instability test: a clinical test for lumbar shear instability. Arch Phys Med Rehabil. 2011 Jun;92(6):913-9. doi: 10.1016/j.apmr.2010.12.042.
- Scholtes SA, Norton BJ, Lang CE, Van Dillen LR. The effect of within-session instruction on lumbopelvic motion during a lower limb movement in people with and people without low back pain. Man Ther. 2010 Oct;15(5):496-501. doi: 10.1016/j.math.2010.05.003. Epub 2010 Jun 2.
- Harris-Hayes M, Van Dillen LR. The inter-tester reliability of physical therapists classifying low back pain problems based on the movement system impairment classification system. PM R. 2009 Feb;1(2):117-26. doi: 10.1016/j.pmrj.2008.08.001. Epub 2008 Dec 27.
- Scholtes SA, Gombatto SP, Van Dillen LR. Differences in lumbopelvic motion between people with and people without low back pain during two lower limb movement tests. Clin Biomech (Bristol, Avon). 2009 Jan;24(1):7-12. doi: 10.1016/j.clinbiomech.2008.09.008. Epub 2008 Nov 5.
- Hoffman SL, Johnson MB, Zou D, Van Dillen LR. Sex differences in lumbopelvic movement patterns during hip medial rotation in people with chronic low back pain. Arch Phys Med Rehabil. 2011 Jul;92(7):1053-9. doi: 10.1016/j.apmr.2011.02.015.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2007
Primary Completion (Actual)
August 1, 2009
Study Completion (Actual)
November 1, 2010
Study Registration Dates
First Submitted
December 4, 2008
First Submitted That Met QC Criteria
December 4, 2008
First Posted (Estimate)
December 5, 2008
Study Record Updates
Last Update Posted (Estimate)
October 22, 2012
Last Update Submitted That Met QC Criteria
October 18, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HD047709-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.